Document text
Principal Investigator: Heinrich Feldmann
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $203,488
Funding agency: National Institute of Allergy and Infectious Diseases
(1) Animal model development: We have established the Syrian hamster model for pathogenesis studies and countermeasure development. Following intranasal inoculation of SARS-CoV-2, hamsters consistently developed moderate broncho-interstitial pneumonia, with high viral lung loads and extensive virus shedding. We determined the infectious dose 50 to be only five infectious particles. (Rosenke et al., Emerg Microbes Infect 2020)
We determined the ability of SARS-CoV-2 to infect domestic pigs via experimental oral/intranasal/intratracheal inoculation, and to transmit to co-housed nave sentinel pigs. None of the inoculated pigs showed evidence of clinical signs, viral replication or specific antibody responses. Moreover, none of the sentinel pigs displayed markers of SARS-CoV-2 infection. Thus, young pigs are not susceptible to infection. (Meekins et al., Emerg Microbes Infect 2020).
We have developed an African green monkey model for assessing SARS-CoV-2 variants. Intranasal Infections with either a contemporary D614G or the UK B.1.1.7 variant caused mild respiratory disease with no significant differences in clinical presentation. Significantly higher levels of viral RNA and infectious virus were found in upper and lower respiratory tract samples and tissues from B.1.1.7 infected animals. Our results indicate that B.1.1.7 infection is associated with increased respiratory replication and shedding but no disease enhancement similar. (Rosenke et al., under review)
(2) Antiviral testing: We have established an in vitro drug screening pipeline that will feed promising candidates into in vivo testing using the Syrian hamster model. (Jarvis et al., Antivir Ther 2020).
We tested peptide-conjugated morpholino oligomers (PPMO) designed to base-pair with sequence in the 5' terminal region or the leader regulatory sequence region of SARS-CoV-2 genomic RNA for their antiviral efficacy in cell culture. PPMOS were highly efficacious, reducing viral titres by up to 4-6 log10 in cell cultures at 48-72 h post-infection. (Rosenke et al., J Antimicrob Chemother 2021).
We assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ) in two animal disease models. The standard human malaria HCQ prophylaxis and treatment did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the Syrian hamster and rhesus macaque disease model. (Rosenke et al., JCI Insight 2020; Funnell et al., Nat Commun 2020).
We showed that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients. (Rosenke et al., Nat Commun 2021).
(3) Host response to infection: Severe coronavirus disease 2019 (COVID-19) has been associated with T cell lymphopenia, but no causal effect of T cell deficiency on disease severity has been established. We studied rhesus macaques that were depleted of either CD4+, CD8+, or both T cell subsets prior to infection. Peak virus loads were similar in all groups, but the resolution of virus in the T cell-depleted animals was slightly delayed compared to that in controls. The T cell-depleted groups developed virus-neutralizing antibody responses and class switched to IgG. When reinfected 6 weeks later, the T cell-depleted animals showed anamnestic immune responses characterized by rapid induction of high-titer virus-neutralizing antibodies, faster control of virus loads, and reduced clinical signs. These results indicate that while T cells play a role in the recovery from acute SARS-CoV-2 infections, their depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severe COVID-19. (Hasenkrug et al., mBio 2021).
We compared African green monkeys inoculated with infectious SARS-CoV-2 or irradiated, inactivated virus to study the dynamics of virus replication throughout the respiratory tract. Genomic RNA from the animals inoculated with the irradiated virus was found to be highly stable, whereas subgenomic RNA, an indicator of viral replication, was found to degrade quickly. We combined this information with single-cell RNA sequencing of cells isolated from the lung and lung-draining mediastinal lymph nodes. Through detection of reads to the viral genome, we were able to determine that replication of the virus in the lungs appeared to occur mainly in pneumocytes, whereas macrophages drove the inflammatory response. Monocyte-derived macrophages recruited to the lungs, rather than tissue-resident alveolar macrophages, were most likely to be responsible for phagocytosis of infected cells and cellular debris early in infection, with their roles switching during clearance of infection. (Speranza et al., Sci Transl Med 2021).
(4) Vaccine development: We have developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery, and immunogenicity. We have shown that intramuscular injection of LION/repRNA-CoV2S elicited robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a prime-only administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2 as well as T cell responses indicative of a Type 1 T helper response. (Erasmus et al., Sci Transl Med 2020).
We studied the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. (Hassan et al., Cell Rep Med 2021).
We further evaluated a DNA vaccine against SARS-CoV-2 in the Syrian hamster model. Hamsters were vaccinated with a DNA-plasmid encoding the SARS-CoV-2 full length spike open reading frame (ORF) before exposure to infectious virus. We tested this vaccine candidate by both intranasal (IN) and intramuscular (IM) routes of administration and complexing with and without an in vivo delivery reagent. Hamsters receiving prime-boost-boost IM-only vaccinations recovered body weight quicker, had decreased lung viral loads, and increased SARS-CoV-2-specific antibody titers compared to control vaccinated animals but, surprisingly, lung pathology was as severe as sham vaccinated controls. The IM/IN combination group showed no efficacy in reducing lung virus titers or pathology. This data demonstrates that in some vaccine contexts, significant antibody responses and decreased viral loads may not be sufficient to prevent lung pathology. (Leventhal et al., Microorganisms 2021).
During a regular visit in Mali, our ICER site, in February, we developed and established diagnostic testing for the emerging SARS-CoV-2. At that time Mali did not have any COVID cases, a situation that has changed dramatically. The ICER site (Point G) is now one of 4 national diagnostic centers for COVID testing in Mali.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Acute><Ad vector><Adenoviral Vector><Adenovirus Vector><African Green Monkey><Alveolar Macrophages><Animal Disease Models><Animals><Antibodies><Antibody Response><Antibody titer measurement><Antiviral Agents><Antiviral Drugs><Antivirals><B.1.1.7><Base Pairing><Blood monocyte><Body Tissues><Body Weight><CD8><CD8B><CD8B1><CD8B1 gene><COVID><COVID infected patient><COVID patient><COVID positive patient><COVID testing><COVID-19><COVID-19 S protein><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture Techniques><Cells><Chad><Chimp><Chimpanzee><Chlorocebus aethiops><Chlorocebus sabaeus><Class Switching><Class Switchings><Clinical><CoV disease><CoV-2><CoV2><Complex><Containment><Cricetinae><DNA Vaccines><Data><Detection><Development><Diagnostic><Diagnostic tests><Disease><Disease model><Disorder><Domestic Pig><Dose><Drug Screening><Drugs><Dysfunction><Emerging Communicable Diseases><Emerging Infectious Diseases><Exposure to><Family suidae><Fostering><Functional disorder><Goals><Golden Hamsters><Golden Syrian Hamsters><Green Monkey><Hamsters><Hamsters Mammals><Human><Hydroxychlorochin><Hydroxychloroquine><IgG><Immune response><Immunize><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunoglobulin G><Immunological response><In Vitro><Infection><Infection prevention><Inflammatory Response><International><Interstitial Lung Inflammation><Interstitial Pneumonia><Interstitial Pneumonitis><Interstitial Pulmonary Inflammation><Intramuscular><Intramuscular Injections><Isotype Switching><Isotype Switchings><LYT3><Length><Lipids><Lower respiratory tract structure><Lung><Lung Respiratory System><Lung diseases><Lymphocytopenia><Lymphopenia><M mulatta><M. mulatta><Macaca mulatta><Malaria><Mali><Marrow monocyte><Mediastinal Lymph Node><Mediastinal lymph node group><Medication><Mesocricetus auratus><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Murine><Mus><Mφ><NIAID><NIH><Naked DNA Vaccines><National Institute of Allergy and Infectious Disease><National Institutes of Health><Natural Resistance><Non-Polyadenylated RNA><ORFs><Open Reading Frames><Oral><Outcome><Oxychlorochin><Oxychloroquine><Paludism><Pan Genus><Pan Species><Pathogenesis><Pathogenicity><Pathology><Peptides><Phagocytosis><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiopathology><Pigs><Plasmodium Infections><Play><Prevent infection><Prophylactic treatment><Prophylaxis><Protein Coding Region><Proteins><Public Health><Pulmonary Body System><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Macrophages><Pulmonary Organ System><Pulmonary Pathology><RNA><RNA Gene Products><Reagent><Recombinant DNA Vaccines><Recovery><Replication Unit><Replicon><Research><Resolution><Respiratory Disease><Respiratory System><Respiratory System Disease><Respiratory System Disorder><Respiratory Tracts><Respiratory tract structure><Rhesus Macaque><Rhesus Monkey><Ribonucleic Acid><Role><Route><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 S protein><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pathogenesis><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Sentinel><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Site><Suidae><Sus scrofa domestica><Swine><Syrian Hamsters><T cell response><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><Testing><Therapeutic><Time><Tissues><Treatment Efficacy><U.K. variant><UK variant><United Kingdom variant><United States National Institutes of Health><Vaccinated><Vaccination><Vaccines><Variant><Variation><Viral><Viral Burden><Viral Diseases><Viral Genome><Viral Load><Viral Load result><Viral Shedding><Viral load measurement><Virus><Virus Diseases><Virus Replication><Virus Shedding><Visit><Wuhan coronavirus><adeno vector><adenovector><animal model development><anti-viral agents><anti-viral drugs><anti-viral efficacy><anti-virals><antibody titering><antiviral efficacy><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><cell culture><communicable disease transmission><corona virus disease><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease testing><coronavirus patient><coronavirus testing><design><designing><develop a vaccine><development of a vaccine><developmental><disease of the lung><disease severity><disease transmission><disorder model><disorder of the lung><drug/agent><evaluate vaccines><genomic RNA><hCoV19><high risk><host response><immune system response><immunogenic><immunogenicity><immunoresponse><in vivo><in vivo evaluation><in vivo testing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infectious disease transmission><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><insight><intervention efficacy><intramuscular drug administration><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lower respiratory tract><lung disorder><lung pathology><macrophage><microorganism><monocyte><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><naturally resistant><neutralizing antibody><non-human primate><nonhuman primate><novel><nucleoside analog><particle><pathogenic virus><pathophysiology><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><plasmid DNA><plasmid vaccine><pneumocyte><porcine><prevent><preventing><prophylactic><pulmonary><recruit><respiratory><response><scRNA-seq><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><single cell RNA-seq><single cell RNAseq><single-cell RNA sequencing><social role><suid><therapeutic efficacy><therapy efficacy><thymus derived lymphocyte><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine development><vaccine evaluation><vaccine for novel coronavirus><vaccine formulation><vaccine screening><vaccine testing><vector vaccine><viral RNA><viral infection><viral multiplication><viral pathogen><viral replication><virus RNA><virus genome><virus infection><virus load><virus multiplication><virus pathogen><virus-induced disease>